Ocrelizumab (Ocrevus) Subcutaneous Injection

Ocrelizumab is a disease-modifying therapy that targets specific immune cells involved in MS progression. Clinical trials have shown it to be highly effective in halting the symptoms of MS. In fact, 97% of patients in trials experienced no relapses or new brain lesions over 48 weeks.

bookings.neurology@onewelbeck.com

02036532045

What is a Ocrelizumab (Ocrevus) Subcutaneous Injection?

Thousands of people with multiple sclerosis (MS) in England are set to benefit from this new, faster treatment option.

Previously, ocrelizumab was administered via intravenous (IV) infusions, which could take up to four hours. The new injection offers a significant reduction in treatment time, allowing patients to spend less time in hospitals.

Ocrelizumab is a disease-modifying therapy that targets specific immune cells involved in MS progression. Clinical trials have shown it to be highly effective in halting the symptoms of MS. In fact, 97% of patients in trials experienced no relapses or new brain lesions over 48 weeks.

 

The injection is expected to not only improve the quality of life for MS patients but also reduce the burden on healthcare resources. It could free up hospital capacity and allow clinicians to focus on other patients.

This new treatment option is particularly beneficial for patients with difficult-to-access veins, who may have previously faced challenges with IV infusions.

Why might you need Ocrevus?

You may need Ocrevus if you have:

What to expect on the day of your appointment

Your appointment will typically involve the following steps:

  1. Diagnosis of MS: This includes neurological scans and clinical assessment.
  2. Pre-medication: You'll take pre-medication (usually antihistamines and anti-inflammatory drugs) about 30 minutes before the infusion.
  3. Subcutaneous infusion: The Ocrevus injection takes approximately 10 minutes.
  4. Observation: You'll be monitored for 60 minutes after the infusion.
  5. Follow-up: You'll have a follow-up clinical review with your treating neurologist.

Risks associated with Ocrevus

Potential risks associated with Ocrevus include:

  • Injection-related responses: Rash, itching, redness
  • Slight suppression of the immune system: Increased risk of infections (e.g., colds, viruses)

Why choose OneWelbeck for Ocrevus?

  • Highly experienced clinical team: Our team has extensive expertise in treating MS and administering Ocrevus.
  • Convenient location in Central London: We're easily accessible for patients in the London area.
  • Easy access to cross-specialty referrals: If needed, we can connect you with other specialists for comprehensive care.
  • Exclusive subcutaneous delivery: We're one of the few facilities in the UK offering the new subcutaneous method of Ocrevus delivery, which is less time-consuming and more efficient than the traditional IV infusion.

Treatment Costs

£14,000

Book a consultation

Oct 2024

MON TUE WED THU FRI SAT SUN

Currently selected day

Available consultations

Click any unavailable day to check availability with similar consultants

Treatment Programme
Ocrelizumab (Ocrevus) Subcutaneous Injection

Image

Doctor Referral Only

You will generally need to get a referral letter from your NHS GP, Private GP, or other doctor to access this service or treatment. Find out more including how we can assist you

Image

Self-Pay Available

This treatment is available for self-paying users. If you would like to see more information on pricing visit our pricing and payments page.

Image

Consultation Required

For this treatment you will need to have a 1-to-1 consultation at OneWelbeck first. To book in with our team of expert clinicians or to find out more about the process contact the relevant centre team.